April Kennedy, MD
Nephrology · Chicago, ILNPI 1487738639
Payments from drug & device makers
Across 252 payments — averaging $7009.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$624K
- Takeda Pharmaceuticals U.S.A., Inc.$502K
- AstraZeneca$464K
- Madrigal Pharmaceuticals$49K
- GSK$48K
- Astrazeneca UK Limited$46K
- plus $33K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $623,707 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $501,882 |
| AstraZeneca(2 entities) | 27 | $463,989 |
| Madrigal Pharmaceuticals | 1 | $49,149 |
| GSK | 9 | $47,940 |
| Astrazeneca UK Limited | 1 | $46,290 |
| Bayer | 10 | $11,599 |
| Boehringer Ingelheim International GmbH | 89 | $10,339 |
| Pfizer | 1 | $9,576 |
| OPKO Pharmaceuticals, LLC | 32 | $518 |
| Amgen(2 entities) | 11 | $440 |
| Calliditas Therapeutics US Inc. | 3 | $169 |
| Mallinckrodt Hospital Products Inc. | 1 | $149 |
| Travere Therapeutics, Inc. | 6 | $140 |
| Vifor Pharma, Inc. | 1 | $92 |
| Novartis | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Fresenius USA Marketing, Inc. | 3 | $61 |
| Ardelyx, Inc. | 2 | $49 |
| Akebia Therapeutics Inc | 3 | $39 |
| Novo Nordisk | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| AbbVie | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$1,766,395 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Chicago
- Myles WolfChicago$22.4M
- Beatrice ConcepcionChicago$2.6M
- Khaleel SayeedChicago$1.7M
- Tamara IsakovaChicago$763K
- William WhittierChicago$668K
- Arlene ChapmanChicago$505K
- Daniel BatlleChicago$491K
- John FriedewaldChicago$472K
- Cybele GhosseinChicago$398K
- Ramin SamChicago$393K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.